Compare Huntington Ingalls Industries Inc (HII) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Mesoblast Limited — how do they compare? Huntington Ingalls Industries Inc trades at $264.76 (market cap $10.44B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Huntington Ingalls Industries Inc is far larger — about 6× Mesoblast Limited's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Mesoblast Limited for 15 Days on average.
| HII | MESO | |
|---|---|---|
Market Cap | $10.44B | $1.75B |
Volume | 440,462 | 239,027 |
Sector | Industrials | Health |
52-Week High | $453.73 | $20.96 |
52-Week Low | $257.05 | $13.19 |
Typical Hold Time | 28 Days | 15 Days |
Enterprise Value | $13.37B | $1.83B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.80, up 1.58% today, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 15.78, net income margin of 5.01%, and a $57.3 billion backlog supporting revenue visibility. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, highlight operational momentum amid consistent earnings beats.
The outlook is supported by strong defense budgets and execution, but risks include project delays and macroeconomic pressures. Analysts are generally positive with a $363.67 consensus target, implying significant upside, though technical indicators suggest near-term caution.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
